Genetron Health Gets CE Mark for its Seq-MRD, Residual Cancer Detection Kit

Beijing, China-based Genetron Health has received CE mark certification for its Seq-MRD B-lymphocyte minimal residual disease detection kit.

The assay tests bone marrow samples collected from patients with B-lymphpocytic leukemia and multiple myeloma before and after treatment.

This approach can detect minimal residual disease and provide a reference for follow-up treatment of cancer survivors, the company said.

Genetron, which specializes in molecular profiling tests, early cancer screening products and companion diagnostics, said it believes the Seq-MRD gene sequencing technology has many potential applications.